Canadian Multicenter Chronic Total Occlusion Registry: Ten-Year Follow-Up Results of Chronic Total Occlusion Revascularization.


Journal

Circulation. Cardiovascular interventions
ISSN: 1941-7632
Titre abrégé: Circ Cardiovasc Interv
Pays: United States
ID NLM: 101499602

Informations de publication

Date de publication:
12 2021
Historique:
entrez: 21 12 2021
pubmed: 22 12 2021
medline: 11 1 2022
Statut: ppublish

Résumé

Chronic total occlusions (CTO) occur in nearly 20% of coronary angiograms. CTO revascularization, either by percutaneous coronary intervention (PCI) or coronary artery bypass grafting surgery (CABG), is infrequently performed, approximately one-third of cases. Long-term outcomes are unknown. The objective of the study was to determine whether early CTO revascularization of patients, either by CABG or PCI, was associated with improved clinical outcomes. One thousand six hundred twenty-four patients from the Canadian CTO registry were followed for at least 9.75 years. Revascularization was performed according to routine clinical practice. Patients were grouped according to CTO revascularization status (PCI or CABG of CTO vessel, CTO revasc) or no CTO revasc (medical therapy only, or PCI/CABG of non-CTO vessels only), within 3 months of initial angiogram. Patients were followed for mortality, revascularization procedures (PCI and CABG), and hospitalizations for acute coronary syndromes and heart failure. Early CTO revasc was performed in 28.2% of patients (17.5% CABG, 10.7% PCI). The CTO revasc group was younger, with more males and generally fewer comorbidities. There was a significantly lower mortality probability at 10 years in the CTO revascularization group (22.7% [95% CI, 19.0%-26.9%]) compared with the no CTO revasc group (36.6% [95% CI, 33.8%-39.5%]). At 10 years, revascularization rates (14.0% versus 22.8%) and acute coronary syndrome hospitalization rates (10.0% versus 16.6%) were significantly lower in the CTO revasc group. Baseline-adjusted analysis showed CTO revasc was associated with significantly lower all-cause mortality (hazard ratio, 0.67 [95% CI, 0.54-0.84]). In both landmark and time varying analyses, association with lower mortality was particularly robust for CTO revascularization by CABG (hazard ratio 0.56 and 0.60, respectively), with a marginally significant result for PCI in the time varying analysis (hazard ratio 0.711 [95% CI, 0.51-0.998]). Early CTO revascularization was associated with significantly lower all-cause mortality, revascularization rates, and hospitalization for acute coronary syndrome at 10 years, and mainly driven by outcomes in patients with CABG.

Sections du résumé

BACKGROUND
Chronic total occlusions (CTO) occur in nearly 20% of coronary angiograms. CTO revascularization, either by percutaneous coronary intervention (PCI) or coronary artery bypass grafting surgery (CABG), is infrequently performed, approximately one-third of cases. Long-term outcomes are unknown. The objective of the study was to determine whether early CTO revascularization of patients, either by CABG or PCI, was associated with improved clinical outcomes.
METHODS
One thousand six hundred twenty-four patients from the Canadian CTO registry were followed for at least 9.75 years. Revascularization was performed according to routine clinical practice. Patients were grouped according to CTO revascularization status (PCI or CABG of CTO vessel, CTO revasc) or no CTO revasc (medical therapy only, or PCI/CABG of non-CTO vessels only), within 3 months of initial angiogram. Patients were followed for mortality, revascularization procedures (PCI and CABG), and hospitalizations for acute coronary syndromes and heart failure.
RESULTS
Early CTO revasc was performed in 28.2% of patients (17.5% CABG, 10.7% PCI). The CTO revasc group was younger, with more males and generally fewer comorbidities. There was a significantly lower mortality probability at 10 years in the CTO revascularization group (22.7% [95% CI, 19.0%-26.9%]) compared with the no CTO revasc group (36.6% [95% CI, 33.8%-39.5%]). At 10 years, revascularization rates (14.0% versus 22.8%) and acute coronary syndrome hospitalization rates (10.0% versus 16.6%) were significantly lower in the CTO revasc group. Baseline-adjusted analysis showed CTO revasc was associated with significantly lower all-cause mortality (hazard ratio, 0.67 [95% CI, 0.54-0.84]). In both landmark and time varying analyses, association with lower mortality was particularly robust for CTO revascularization by CABG (hazard ratio 0.56 and 0.60, respectively), with a marginally significant result for PCI in the time varying analysis (hazard ratio 0.711 [95% CI, 0.51-0.998]).
CONCLUSIONS
Early CTO revascularization was associated with significantly lower all-cause mortality, revascularization rates, and hospitalization for acute coronary syndrome at 10 years, and mainly driven by outcomes in patients with CABG.

Identifiants

pubmed: 34932391
doi: 10.1161/CIRCINTERVENTIONS.121.010546
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e010546

Subventions

Organisme : Canadian Institute of Health Research
ID : CTP 82943

Commentaires et corrections

Type : CommentIn

Auteurs

Bradley H Strauss (BH)

Schulich Heart Program, Sunnybrook Health Sciences Centre (B.H.S., G.E.-G., W.A., H.C.W.).
University of Toronto, Ontario, Canada (B.H.S., A.N.C., K.A.H., F.Q., H.C.W.).

Merril L Knudtson (ML)

Libin Cardiovascular Institute of Alberta, Calgary, Canada (M.L.K., P.D.G.).

Asim N Cheema (AN)

Terrence Donnelly Heart Center, St. Michael's Hospital (A.N.C.).
University of Toronto, Ontario, Canada (B.H.S., A.N.C., K.A.H., F.Q., H.C.W.).

P Diane Galbraith (PD)

Libin Cardiovascular Institute of Alberta, Calgary, Canada (M.L.K., P.D.G.).

Gabby Elbaz-Greener (G)

Schulich Heart Program, Sunnybrook Health Sciences Centre (B.H.S., G.E.-G., W.A., H.C.W.).
Now with Hadassah Medical Center, Hebrew University, Jerusalem, Israel (G.E.-G.).

Wael Abuzeid (W)

Schulich Heart Program, Sunnybrook Health Sciences Centre (B.H.S., G.E.-G., W.A., H.C.W.).
Now with Kingston General Hospital, Queen's University, Kingston, Ontario, Canada (W.A.).

Kayley A Henning (KA)

University of Toronto, Ontario, Canada (B.H.S., A.N.C., K.A.H., F.Q., H.C.W.).
ICES, Toronto, Ontario (K.A.H., F.Q., H.C.W.).

Feng Qiu (F)

University of Toronto, Ontario, Canada (B.H.S., A.N.C., K.A.H., F.Q., H.C.W.).
ICES, Toronto, Ontario (K.A.H., F.Q., H.C.W.).

Harindra C Wijeysundera (HC)

Schulich Heart Program, Sunnybrook Health Sciences Centre (B.H.S., G.E.-G., W.A., H.C.W.).
University of Toronto, Ontario, Canada (B.H.S., A.N.C., K.A.H., F.Q., H.C.W.).
ICES, Toronto, Ontario (K.A.H., F.Q., H.C.W.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH